BMN 255
/ BioMarin
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 11, 2024
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: BioMarin Pharmaceutical | N=24 ➔ 0 | Trial completion date: Oct 2024 ➔ Mar 2024 | Recruiting ➔ Withdrawn | Trial primary completion date: Jul 2024 ➔ Mar 2024
Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Renal Calculi • Renal Disease
January 01, 2024
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: BioMarin Pharmaceutical
Trial completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Renal Calculi • Renal Disease
November 18, 2023
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: BioMarin Pharmaceutical
New P1 trial • Hepatology • Nephrology • Non-alcoholic Fatty Liver Disease • Renal Calculi • Renal Disease
1 to 3
Of
3
Go to page
1